BBlogFlow

Nominations open for 2027 Manitoba Healthy Aging Awards - DiscoverWestman

·Oct 8, 2026
Source: DiscoverWestman
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

Nominations are now being accepted for the 2027 Manitoba Healthy Aging Awards, which recognize Manitobans who make a difference in the lives of older adults, Health, Seniors and Long-Term Care Minister Uzoma Asagwara announced yesterday.

“Older Manitobans make our communities stronger every day and these awards are about recognizing the people who give their time, energy and leadership to help others age well,” said Asagwara. “Whether they are supporting mental wellness, bringing generations together, helping seniors stay active or advocating for better care, we want to celebrate the people making a real difference in communities across Manitoba.”

This article is an excerpt. To read the full content, visit the original source. DiscoverWestman

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·